作者
Claudia Proto,M. Ganzinelli,Sara Manglaviti,Martina Imbimbo,Giulia Galli,Mirko Marabese,Fabiana Zollo,M.F. Alvisi,M. Perrino,Nadia Cordua,Federica Borea,Fabio De Vincenzo,A. Chella,Susanna Cappelli,E. Pardini,Z. Ballatore,A. Lucarelli,Elisa Ambrosini,Mariateresa Giuliano,Erica Pietroluongo,C. Mulargiu,Agnese Fabbri,Arsela Prelaj,Mario Occhipinti,M. Brambilla,L. Mazzeo,T. Beninato,R. Vigorito,Margherita Ruggirello,Francesca Greco,G. Calareso,Daniela Miliziano,Eliana Rulli,Irene De Simone,Valter Torri,F.G.M. De Braud,G. Pasello,Pietro De Placido,Romeo S. Berardi,Iacopo Petrini,Paolo Andrea Zucali,Marina Chiara Garassino,G. Lo Russo
摘要
Thymic carcinoma (TC) is a rare tumor with aggressive behavior. Chemotherapy with carboplatin plus paclitaxel represents the treatment of choice for advanced disease. Antiangiogenic drugs, including ramucirumab, have shown activity in previously treated patients. RELEVENT trial was designed to evaluate the activity and safety of ramucirumab plus chemotherapy as first-line treatment in advanced TC.
Grayball
迟大猫
开心岩
VDC
MchemG
迷人秋烟
iNk
小白
竹筏过海
笔记本
YSM
小杨同学
zho
遇上就这样吧
归尘
Xiaoxiao
从容芮
morena
青木香
nozero
皖公网安备34019202002308
